![Selective Activation of p38 Mitogen-Activated Protein Kinase in Dopaminergic Neurons of Substantia Nigra Leads to Nuclear Translocation of p53 in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice | Journal of Neuroscience Selective Activation of p38 Mitogen-Activated Protein Kinase in Dopaminergic Neurons of Substantia Nigra Leads to Nuclear Translocation of p53 in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice | Journal of Neuroscience](https://www.jneurosci.org/content/jneuro/28/47/12500/F2.large.jpg)
Selective Activation of p38 Mitogen-Activated Protein Kinase in Dopaminergic Neurons of Substantia Nigra Leads to Nuclear Translocation of p53 in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Treated Mice | Journal of Neuroscience
![Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41418-020-00654-2/MediaObjects/41418_2020_654_Fig1_HTML.png)
Neuronal cell life, death, and axonal degeneration as regulated by the BCL-2 family proteins | Cell Death & Differentiation
![Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications: Molecular Therapy - Nucleic Acids Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications: Molecular Therapy - Nucleic Acids](https://www.cell.com/cms/attachment/b186e35c-dd0c-4135-9a04-f6351d102824/fx1_lrg.jpg)
Noncoding RNAs in pediatric brain tumors: Molecular functions and pathological implications: Molecular Therapy - Nucleic Acids
![Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/d2c25b15-2f11-4698-a532-bf7c183b6a74/gr1.gif)